155 related articles for article (PubMed ID: 6783287)
1. Effect of active and passive immunization on the development of experimental Pseudomonas aeruginosa pyelonephritis in mice.
Petit JC; Sicard D; Bayo S; Daguet GL
Can J Microbiol; 1981 Jan; 27(1):93-7. PubMed ID: 6783287
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
3. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
Mates A; Zand P
J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
[TBL] [Abstract][Full Text] [Related]
4. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
5. Divalent flagellin immunotherapy provides homologous and heterologous protection in experimental urinary tract infections in mice.
Sabharwal N; Chhibber S; Harjai K
Int J Med Microbiol; 2016 Jan; 306(1):29-37. PubMed ID: 26655680
[TBL] [Abstract][Full Text] [Related]
6. [Antigenic properties of Pseudomonas aeruginosa anatoxin and the protective action of antitoxic anti-Pseudomonas aeruginosa serum].
Podgornaia LG; Dziuban NF
Zh Mikrobiol Epidemiol Immunobiol; 1986 Jun; (6):67-9. PubMed ID: 3092510
[TBL] [Abstract][Full Text] [Related]
7. Active and passive immunization with Pseudomonas aeruginosa ribosomal vaccines and antisera in the burned rat model.
Lieberman MM; Walker HL; Ayala E; Chapa I
J Surg Res; 1986 Feb; 40(2):138-44. PubMed ID: 3080639
[TBL] [Abstract][Full Text] [Related]
8. [Effect of the protective properties of antisera and immunoglobulin to antigens of Pseudomonas aeruginosa slime].
Zaĭdner IG; Stanislavskiĭ ES; Gladus MA
Zh Mikrobiol Epidemiol Immunobiol; 1980 Oct; (10):52-7. PubMed ID: 6778023
[TBL] [Abstract][Full Text] [Related]
9. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.
Pennington JE; Pier GB; Sadoff JC; Small GJ
Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209
[TBL] [Abstract][Full Text] [Related]
10. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
[TBL] [Abstract][Full Text] [Related]
11. Systemic and topical protection studies using Pseudomonas aeruginosa flagella in an ocular model of infection.
Rudner XL; Hazlett LD; Berk RS
Curr Eye Res; 1992 Aug; 11(8):727-38. PubMed ID: 1424719
[TBL] [Abstract][Full Text] [Related]
12. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
[TBL] [Abstract][Full Text] [Related]
13. Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein.
Yushkova NA; Kholodkova EV; Korobova TS; Stanislavsky ES
Acta Microbiol Hung; 1986; 33(2):147-56. PubMed ID: 3101393
[TBL] [Abstract][Full Text] [Related]
14. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH
J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894
[TBL] [Abstract][Full Text] [Related]
15. Passive immunisation against Pseudomonas aeruginosa recombinant flagellin in an experimental model of burn wound sepsis.
Faezi S; Sattari M; Mahdavi M; Roudkenar MH
Burns; 2011 Aug; 37(5):865-72. PubMed ID: 21334822
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
[TBL] [Abstract][Full Text] [Related]
17. [Experimental study of the dynamics of the formation of protective antibodies to the antigens of the slime of Pseudomonas aeruginosa].
Iushkova NA; Stanislavskiĭ ES; Landsman NM
Zh Mikrobiol Epidemiol Immunobiol; 1983 Mar; (3):78-83. PubMed ID: 6405564
[TBL] [Abstract][Full Text] [Related]
18. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
19. Antigenic relationship between the common antigen (OEP) of Pseudomonas aeruginosa and Vibrio cholerae.
Hirao Y; Homma JY
Infect Immun; 1978 Feb; 19(2):373-7. PubMed ID: 75846
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of properties of Pseudomonas aeruginosa recombinant outer membrane protein F (OprF)].
Zlygostev SA; Gataullin AG; Kaloshin AA; Mikhaĭlova NA; Zverev VV
Zh Mikrobiol Epidemiol Immunobiol; 2006; (7):43-7. PubMed ID: 17297879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
